Phase 2 Asthma Data: 66% Treatment Failure Reduction, but Primary Endpoint Misses Significance
CNTB sits 41% above its 52-week low of $1.23 on elevated volume (3.8× avg).
Summary
Connect Biopharma reported Phase 2 topline data for rademikibart in acute asthma exacerbations. The drug showed a 66% reduction in treatment failure and significant lung function improvement, but the primary endpoint missed statistical significance due to a lower-than-expected placebo event rate.
Key Events · Product Development and Regulatory · CNTB
-
Phase 2 Asthma Topline Results
Rademikibart reduced treatment failure rate by 66% vs placebo (2.5% vs 7.4%, p=0.153), missing statistical significance due to a lower-than-projected placebo event rate.
-
Lung Function Improvement
Statistically significant 130 mL greater improvement in post-bronchodilator FEV1 at Day 7 vs placebo (250 mL vs 120 mL, p=0.023).
-
Safety Profile
Well tolerated with no new safety signals; one SAE in rademikibart arm vs three in placebo arm.
-
Next Milestones
COPD topline data expected later this month, followed by FDA meeting to align on Phase 3 program using Day 7 FEV1 as primary endpoint.
Analysis · CNTB · Life Sciences
Rademikibart delivered a clinically meaningful 66% reduction in treatment failure events and a statistically significant improvement in lung function, yet the primary endpoint missed statistical significance because the placebo arm performed far better than projected. The company will use the Day 7 FEV1 improvement as the proposed Phase 3 endpoint and plans to meet with the FDA after reporting COPD data later this month. For a company with a one-year cash runway, these results keep the program alive but leave regulatory risk unresolved.
How filings like this one have moved
In the 30 days to Oct 3, 2026, 28.9% of the 1668 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CNTB was trading at $1.73 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $108.6M. The 52-week trading range was $1.23 to $3.82. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.